Athira Pharma Inc expected to post a loss of 79 cents a share - Earnings Preview

LeonaBio

07/05/2024 12:30

* Athira Pharma Inc  ATHA.OQ   ATHA.O  is expected to show
no
change in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Athira Pharma Inc is for
a
loss of 79 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Athira
Pharma Inc
is $4.50​, above​ its last closing price of $1.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.98       -0.96      -0.71     Beat    26
 Sep. 30 2023  -0.82       -0.81      -0.87     Missed  -6.9
 Jun. 30 2023  -0.79       -0.78      -0.78     Met     0.4​
 Mar. 31 2023  -0.62       -0.62      -0.73     Missed  -17
 ​​Dec.                    -0.67      -0.53     Beat    20.9
 31 2022                                                
 Sep. 30 2022  -0.65       -0.63      -0.53     Beat    16.3​
 Jun. 30 2022  -0.64       -0.64      -0.65     Missed  -1.8
 Mar. 31 2022  -0.53       -0.55      -0.56     Missed  -1.8
 This summary was machine generated May 7 at 11:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)